Rapid antigen testing remains an essential tool in managing respiratory illnesses across Australia. With COVID-19 continuing to circulate alongside seasonal influenza, timely and accessible diagnostic solutions are critical for effective infection control.
During the Australian winter months, respiratory illnesses such as COVID-19 and Influenza A and B increase, placing added pressure on healthcare systems and workplaces. This seasonal rise highlights the importance of early detection, prevention, and effective outbreak management.
Combined COVID-19 and influenza antigen tests provide a streamlined approach by detecting multiple viruses from a single nasal sample. This reduces testing complexity while supporting faster decision making in clinical and operational environments.
As organisations prioritise safety and continuity, combined rapid antigen testing is widely used across healthcare, aged care, industrial, corporate, education, and frontline service sectors to support workforce health and minimise disruption.
What Is Combined COVID-19 and Flu Antigen Testing?
Combined antigen tests detect viral proteins from multiple respiratory infections in a single test, including SARS-CoV-2, Influenza A, and Influenza B. They are commonly used to support faster decision making and reduce the need for multiple tests.
Using lateral flow technology, these tests analyse a nasal swab sample to identify viral antigens. Results are typically available within approximately 15 minutes, enabling rapid screening and timely action.
Why Is Combined Testing Important During Cold and Flu Season?
Cold and flu season in Australia brings a higher incidence of respiratory illness, often with overlapping symptoms such as fever, cough, and fatigue. This makes testing essential for accurate identification.
Combined testing supports early detection of circulating viruses, enabling faster isolation and response. This is particularly important during winter, when outbreaks can spread quickly across workplaces, healthcare settings, and communities.
By identifying the cause of illness sooner, organisations can implement appropriate infection control measures and reduce transmission risk.
What Are the Key Benefits for Healthcare and Industry?
Combined antigen testing offers clear advantages across clinical and non-clinical environments. Rapid results enable immediate decisions regarding isolation, treatment, or further testing, which is critical during peak illness periods.
Using a single test to detect multiple viruses improves efficiency by reducing time, cost, and resource use. This is especially valuable in industries where workforce continuity is essential.
Early detection also supports infection control, with Australian Government guidance highlighting the importance of timely testing. The nasal swab method further improves usability and supports higher compliance across users.
How Should Rapid Antigen Tests Be Used Effectively?
To ensure reliable results, rapid antigen tests should be used in accordance with recommended procedures.
- Preparation is essential. Instructions should be reviewed carefully, and proper nasal swab technique must be followed to ensure accurate sample collection.
- Testing should be conducted when symptoms are present or following known exposure. Results must be read within the specified timeframe.
- Safe disposal is also important. Used components should be discarded in line with local guidelines to support hygiene and infection control practices.
What Is the EasyTest Combi Nasal Test Kit?
The EasyTest SARS-CoV-2 A+B Antigen Combi Nasal Test Kit is a combined rapid antigen solution designed to detect COVID-19 and Influenza A and B using a single nasal sample.
This test kit supports efficient respiratory screening across healthcare, workplaces, and community settings. Key features include multi-virus detection, rapid results in approximately 15 minutes, and a user-friendly nasal swab format. The multi-pack configuration also supports repeated or group testing.
Why Choose the EasyTest Combi Kit from Livingstone?
Livingstone International is a trusted supplier to healthcare providers and organisations across Australia, known for delivering reliable medical and diagnostic solutions.
The EasyTest Combi Kit offers a practical combination of speed, convenience, and multi-virus detection, making it well suited for respiratory screening during peak seasonal periods. It supports efficient testing across industries while helping maintain safe environments.
Backed by Livingstone’s commitment to quality, this solution provides confidence in both performance and supply reliability.
What Should You Do After a Positive Test Result?
A positive result for COVID-19 or influenza should be managed promptly to reduce transmission risk. Individuals should follow current public health guidance, including isolating where required and avoiding contact with others.
Workplaces and healthcare settings should implement appropriate infection control measures, such as notifying relevant personnel and reinforcing hygiene practices.
If symptoms worsen or there is uncertainty about results, further medical advice or confirmatory testing may be required. Early action is essential in limiting spread, particularly during winter.
Combined COVID-19 and influenza rapid antigen tests provide a practical solution for respiratory screening, particularly during Australia’s cold and flu season. By detecting multiple viruses from a single sample, they improve efficiency while supporting faster decision making.
Across healthcare and industry, these solutions strengthen infection control and help maintain safe, productive environments. As seasonal illness continues to impact communities, early detection and proactive testing remain essential for effective winter preparedness.
References
- Therapeutic Goods Administration (TGA) 2026, COVID-19 rapid antigen self-tests that are approved in Australia, Australian Government, viewed May 2026, https://www.tga.gov.au/resources/explore-topic/covid-19/covid-19-tests/covid-19-rapid-antigen-self-tests-are-approved-australia.
- Department of Health and Aged Care 2025, COVID-19 testing guidance, Australian Government, Australian Government, viewed May 2026, https://www.health.gov.au/topics/covid-19/testing.
- Therapeutic Goods Administration (TGA) 2024, COVID-19 rapid antigen self-tests and combination tests guidance, Australian Government, viewed May 2026, https://www.tga.gov.au/resources/explore-topic/covid-19/covid-19-tests/covid-19-rapid-antigen-self-tests-home-use.
- Therapeutic Goods Administration (TGA) 2024, Clinical performance requirements for influenza rapid antigen tests, Australian Government, viewed May 2026, https://www.tga.gov.au/resources/guidance/clinical-performance-evaluation-and-risk-management-seasonal-influenza-rapid-antigen-tests.
